Sign in to continue reading...

Amman Stock Exchange Daily Report - 19 December

IB Insights
By IB Insights
5 years ago
Amman Stock Exchange Daily Report - 19 December

Create FREE account or Login to add your comment
Comments (0)


  1. Amman Stock Exchange 19-Dec-17 AMMAN SE GENERAL INDEX 2 ,200 Close % Change 2,138.52 0.45% Year-to-Date (YTD) -1.46% Daily Volume (shares) 4,300,000 Daily Turnover (JOD) 5,700,000 6 MONTHS INDEX PERFORMANCE 2,180 2,160 2,140 2,120 2,100 2,080 2,060 2,040 2,020 Best Performing Companies UNITED FINANCIAL INVESTMENTS AMMOUN INTERNATIONAL FOR INV SINIORA FOOD INDUSTRIES CO JORDAN DUTY FREE SHOP NATIONAL CABLE & WIRE MANUF Worst Performing Companies % Change 7.25 4.88 4.65 3.83 3.33 Top Traded Companies by Value (JOD) DEERA INVESTMENT & REAL ESTA METHAQ REAL ESTATE INVESTMEN UNION INVESTMENT CORP ARAB BANK PLC BANK OF JORDAN * Source: Bloomberg INTL CO FOR MEDICAL INVEST AL-BILAD MEDICAL SERVICES JORDANIAN REAL ESTATE FOR DE EL-ZAY READY WEAR MANUF CO ARABIAN AVIATION INVESTMENT % Change (3.37) (3.53) (4.00) (4.00) (4.09) Top Traded Companies by Volume (Shares) 895,131 774,887 325,623 310,197 256,734 DEERA INVESTMENT & REAL ESTA METHAQ REAL ESTATE INVESTMEN UNION INVESTMENT CORP SPECIALIZED INVESTMENT COMPO UNITED FINANCIAL INVESTMENTS 1,064,750 435,261 274,947 115,800 114,762
  2. Macroeconomic & Corporate News Palestinian billionaire Masri back in Amman after release in S.Arabia- family source Hikma Pharmaceuticals Plc has won exclusive rights to distribute and market its third biosimilar drug - a copy of Roche's blood cancer treatment Rituxanin - in the Middle East and North African markets, it said on Tuesday. The Jordan-based drugmaker agreed on the licensing deal with Celltrion to market the South Korea-based biopharmaceutical firm's Truxima, a copy of Roche's blockbuster blood cancer medicine, also known as MabThera. Truxima, the first biosimilar cancer drug to hit the European market in February, is used to treat patients with non-Hodgkin's lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis and and microscopic polyangiitis. Jordan's Hikma wins right to market Roche drug copy in Middle East and North Africa Water Minister Hazem El Nasser on Sunday met with a Korean parliamentary delegation headed by Vice Speaker of the Korean National Assembly Shim Jae-chul, and discussed challenges facing the Kingdom due to the Syrian refugee crisis, with a special focus on the water sector.The minister called for increasing support to water-stressed refugee host countries, adding that Jordan was one of the first countries in the region and the world to adopt programmes to enhance scarce water resources, the Jordan News Agency, Petra, reported.He also referred to the strategic partnership between Jordan’s water sector and Korean public and private institutions that financed a number of water projects across the Kingdom.The Korean official highlighted the importance of providing all forms of support to Jordan to enable it to carry out water projects that would positively reflect on its economic and social environment. Water Ministry to float tender for mega solar plant in Jordan The Ministry of Water and Irrigation will float next month a tender for establishing a mega solar plant in the south of the Kingdom to power its major water projects, a senior government official said on Thursday. The studies and blueprints of the solar plant project are in their final phases, Minister of Water and Irrigation Hazim El Naser said, noting that it is one of the ministry’s strategic projects to increase its reliance on clean renewable energy while reducing its power consumption, which totals 14 per cent of the country’s total power production.“The project will be constructed in Disi District within lands owned by the Water Authority of Jordan. It will generate 24 megawatts per year,” Naser told The Jordan Times in a phone interview.The minister highlighted that studies will be * Source: Bloomberg, Jordan Times, Zawya Disclaimer Awraq Investments and its affiliates obtain information from sources they believe to be reliable, but do not warrant its accuracy or fitness for a particular purpose, and disclaim for themselves and their information providers all liability arising from the use. The Information in this publication is provided in good faith for informational purposes only. The information provided is not offered as tax, legal, or investment advice, or an offer to buy or sell securities or otherwise. The information provided in this publication may be displayed and printed for your personal, non-commercial use only. You may not reproduce, re-transmit, distribute, disseminate, sell, publish, broadcast, or circulate the information in any form or media to anyone, without the expressed written consent of Awraq Investments. Awraq Investments is not liable for any loss resulting from any action taken or reliance made by any person on any information or material posted by it. You should make your own inquiries and seek independent advice from relevant industry professionals before acting or relying on any information or material made available to you in this publication. You rely on this information at your own risk. Awraq Investments, its subsidiaries, parent, and/or any connected parties, may act or trade and/or enter into any transaction that maybe inconsistent or disregard any information contained herein.